Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 16/20 | 0.85 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.68 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | HDAC4 | P56524 | 7/20 | 0.56 |
| ▸ | MEF2D | Q14814 | 3/20 | 0.56 |
| ▸ | EP300 | Q09472 | 1/20 | 0.56 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.49 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.49 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.49 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.49 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.49 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.49 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13928111 | 1.00 | HDAC1 (0.85) | HDAC1HDAC6HTTHDAC4MEF2D | |
| SCHEMBL8329131 | 0.92 | HDAC1 (1.00) | HDAC1HDAC6HDAC4MEF2DEP300 | |
| SCHEMBL14254995 | 0.92 | HDAC1 (1.00) | HDAC1HDAC6HDAC4MEF2DEP300 | |
| SCHEMBL23682998 | 0.85 | HDAC1 (0.81) | HDAC1HDAC6HDAC4MEF2DEP300 | |
| SCHEMBL13928109 | 0.82 | HDAC1 (0.85) | HDAC1HDAC6HDAC4MEF2DHDAC3 | |
| SCHEMBL8311632 | 0.82 | HDAC1 (0.85) | HDAC1HDAC6HDAC4MEF2DHDAC3 | |
| SCHEMBL13183169 | 0.82 | HDAC1 (1.00) | HDAC1HDAC6HDAC4MEF2DEP300 | |
| SCHEMBL13159671 | 0.82 | HDAC1 (1.00) | HDAC1HDAC6HDAC4MEF2DEP300 | |
| SCHEMBL13477816 | 0.82 | HDAC1 (0.82) | HDAC1HDAC6HDAC4MEF2DEP300 | |
| SCHEMBL14254994 | 0.82 | HDAC4 (0.66) | HDAC1HDAC6HDAC4MEF2DHDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7799803-B2 | Hydroxamic acid compounds and methods of use thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2010-09-21 | — | — | US | disclosed |
| US-7799803-B2 | Hydroxamic acid compounds and methods of use thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2010-09-21 | — | — | US | disclosed |
| US-20070155785-A1 | Hydroxamic acid compounds and methods of use thereof | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2007-07-05 | — | — | US | disclosed |
| US-20070155785-A1 | Hydroxamic acid compounds and methods of use thereof | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2007-07-05 | — | — | US | disclosed |
| US-7199134-B2 | Hydroxamic acid compounds and methods of use thereof | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2007-04-03 | — | — | US | disclosed |
| US-7199134-B2 | Hydroxamic acid compounds and methods of use thereof | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2007-04-03 | — | — | US | disclosed |
| WO-2004089293-A2 | HYDROXAMIC ACID COMPOUNDS AND METHODS OF USE THEREOF | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2004-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155785-A1 | Hydroxamic acid compounds and methods of use thereof | HDAC5, BRDT, HDAC1 | HDAC1 3/4885HDAC6 5/4885HTT 94/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.